The various aggregation states of β-amyloid 1-42 mediate different effects on oxidative stress, neurodegeneration, and BACE-1 expression

Free Radical Biology and Medicine

Volumn 41, Issue 2, 2006, Pages 202-212

  Tamagno, Elena ^a   Bardini, Paola ^a   Guglielmotto, Michela ^a   Danni, Oliviero ^a   Tabaton, Massimo ^b  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

Alzheimer disease; BACE 1; Fibrillar A 1 42; Free radicals; Oligomeric A 1 42; Oxidative stress; Prefibrillar A 1 42

Indexed keywords

4 HYDROXYNONENAL; AMYLOID BETA PROTEIN[1-42]; BETA SECRETASE; BETA SECRETASE 1; BIOLOGICAL MARKER; HYDROGEN PEROXIDE; OLIGOMER; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; NERVE CELL NECROSIS; NERVE DEGENERATION; NEUROFIBRILLARY TANGLE; NEUROTOXICITY; NUCLEOTIDE SEQUENCE; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN EXPRESSION;

AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN; AMYLOID PRECURSOR PROTEIN SECRETASES; ASPARTIC ACID ENDOPEPTIDASES; ASPARTIC ENDOPEPTIDASES; BASE SEQUENCE; CELL DEATH; CELL LINE; DNA PRIMERS; HUMANS; OXIDATIVE STRESS; PEPTIDE FRAGMENTS; PROTEIN BINDING; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 33745228920     PISSN: 08915849     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2006.01.021     Document Type: Article

References (57)

1. Braak H., Braak E., and Bohl J. Staging of Alzheimer-related cortical destruction. Eur. Neurol. 33 (1993) 403-408
2. Jellinger K.A. The neuropathological diagnosis of Alzheimer disease. J. Neural Transm. Suppl. 53 (1998) 97-118
3. Selkoe D.J. Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev. 81 (2001) 741-766
4. Vassar R., Bennet B.D., Babu-Khan S., Kahn S., Mendiaz E.A., Denis P., Teplow D.B., Ross S., Amarante P., Loeloff R., Luo Y., Fisher S., Fuller J., Edenson S., Lile J., Jarosinski M.A., Biere A.L., Curran E., Burgess T., Louis J.C., Collins F., Treanor J., Rogers G., and Citron M. β-Secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 286 (1999) 735-741
5. Yan R., Bienkoski M.J., Shuck M.E., Miao H., Tory M.C., Pauley A.M., Brashler J.R., Stratman N.C., Mathews W.R., Bulh A.E., Carter D.B., Tomasselli A.G., Parodi L.A., Heinrikson R.L., and Gurney M.E. Membrane anchored aspartic protease with Alzheimer's disease β-secretase activity. Nature 402 (1999) 533-537
6. Sinha S., Anderson J.P., Barbour R., Basi G.S., Caccavelo R., Davis D., Doan M., Dovey H.F., Frigon N., Hong J., Jacobson-Croak K., Jewett N., Keim P., Knops J., Lieberburg I., Power M., Tan H., Tatsuno G., Tung J., Schenk D., Seubert P., Suomensaari S.M., Wang S., Walzer D., Zhao J., McConlog L., and John V. Purification and cloning of amyloid precursor protein β-secretase from human brain. Nature 402 (1999) 537-540
7. Hussain I., Powell D., Howlett D.R., Tew D.G., Meek T.D., Chapman C., Gloger I.S., Murphy K.E., Soutan C.D., Ryan D.M., Smith T.S., Simmons D.L., Walsh F.S., Dingwall C., and Christie G. Identification of a novel aspartic protease (Asp-2) as β-secretase. Mol. Cell. Neurosci. 14 (1999) 419-427
8. Lin X., Koelsch G., Wu S., Downs D., Dashti A., and Tang J. Human aspartic protease memapsin 2 cleaves the beta-secretase site of beta-amyloid precursor protein. Proc. Natl. Acad. Sci. USA 97 (2000) 1456-1460
9. Roberds S.L., Anderson J., Basi G., Bienkowski M.J., Branstetter D.G., Chen K.S., Freedman S.B., Frigon N.L., Games D., Hu K., Johnson-Wood K., Kappenman K.E., Kawabe T.T., Kola I., Kuehn R., Lee M., Liu W., Motter R., Nichols N.F., Power M., Robertson D.W., Schenk D., Schoor M., Shopp G.M., Shuck M.E., Sinha S., Svensson K.A., Tatsuno G., Tintrup H., Wijsman J., Wright S., and McConlogue L. BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer's disease therapeutics. Hum. Mol. Genet. 10 (2001) 1317-1324
10. Selkoe D.J. Alzheimer's disease: a central role for amyloid. J. Neuropathol. Exp. Neurol. 53 (1994) 438-447
11. Drouet B., Pincon-Raymond M., Chambaz J., and Pillot T. Molecular basis of Alzheimer's disease. Cell. Mol. Life Sci. 57 (2000) 705-715
12. Yankner B.A. Mechanisms of neuronal degeneration in Alzheimer's disease. Neuron 16 (1996) 921-932
13. Gong Y., Chang L., Viola K.L., Lacor P.N., Lambert M.P., Finch C.E., Krafft G.A., and Klein W.L. Alzheimer's disease-affected brain: presence of oligomeric Aβ ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc. Natl. Acad. Sci. USA 100 (2003) 10417-10422
14. Kayed R., Head E., Thompson J.L., McIntire T.M., Milton S.C., Cotman C.W., and Glabe C.G. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300 (2003) 486-489
15. Koistinaho M., Ort M., Cimadevilla J.M., Vondrous R., Cordell B., Koistinaho J., Bures J., and Higgins L.S. Specific spatial learning deficits become severe with age in beta-amyloid precursor protein transgenic mice that harbor diffuse beta-amyloid deposits but do not form plaques. Proc. Natl. Acad. Sci. USA 98 (2001) 14675-14680
16. Chui D.H., Tanahashi H., Ozawa K., Ikeda S., Checler F., Ueda O., Suzuki H., Araki W., Inoue H., Shirotani K., Takahashi K., Gallyas F., and Tabira T. Transgenic mice with Alzheimer presenilin 1 mutations show accelerated neurodegeneration without amyloid plaque formation. Nat. Med. 5 (1999) 560-564
17. Nunomura A., Perry G., Aliev G., Hirai K., Takeda A., Balraj E.K., Jones P.K., Ghanbari H., Wataya T., Shimohama S., Chiba S., Atwood C.S., Petersen R.B., and Smith M.A. Oxidative damage is the earliest event in Alzheimer disease. J. Neuropathol. Exp. Neurol. 60 (2001) 759-767
18. Behl C., Davis J.B., Lesley R., and Schubert D. Hydrogen peroxide mediates amyloid beta protein toxicity. Cell 77 (1994) 817-827
19. Yatin S.M., Aksenova M., Aksenov M., Markesbery W.R., Aulick T., and Butterfield D.A. Temporal relations among amyloid beta-peptide-induced free-radical oxidative stress, neuronal toxicity, and neuronal defensive responses. J. Mol. Neurosci. 11 (1998) 183-197
20. Harkany T., Abraham I., Konya C., Nyakas C., Zarandi M., Penke B., and Luiten P.G. Mechanisms of beta-amyloid neurotoxicity: perspectives of pharmacotherapy. Rev. Neurosci. 11 (2000) 329-382
21. Paola D., Domenicotti C., Nitti M., Vitali A., Borghi R., Cottalasso D., Zaccheo D., Odetti P., Strocchi P., Marinari U.M., Tabaton M., and Pronzato M.A. Oxidative stress induces increase in intracellular amyloid β-protein production and selective activation of βI and βII PKCs in NT2 cells. Biochem. Biophys. Res. Commun. 268 (2000) 642-646
22. Tamagno E., Parola M., Bardini P., Piccini A., Borghi R., Guglielmotto M., Santoro G., Davit A., Danni O., Smith M.A., Perry G., and Tabaton M. Beta-site APP cleaving enzyme up-regulation induced by 4-hydroxynonenal is mediated by stress-activated protein kinases pathways. J. Neurochem. 92 (2005) 628-636
23. 2 neurons. Neurobiol. Dis. 10 (2002) 279-288
24. 2 neurons exposed to oxidative stress. Neurobiol. Dis. 14 (2003) 291-301
25. Kao S.C., Krichevsky A.M., Kosik K.S., and Tsai L.H. BACE1 suppression by RNA interference in primary cortical neurons. J. Biol. Chem. 279 (2004) 1942-1949
26. Floyd R.A., and Hensley K. Oxidative stress in brain aging: implications for therapeutics of neurodegenerative diseases. Neurobiol. Aging 23 (2002) 795-807
27. Walsh D.M., Hartley D.M., Kusumoto Y., Fezoui Y., Condron M.M., Lomakin A., Benedek G.B., Selkoe D.J., and Teplow D.B. Amyloid beta-protein fibrillogenesis: structure and biological activity of protofibrillar intermediates. J. Biol. Chem. 274 (1999) 25945-25952
28. Dahlgren K.N., Manelli A.M., Blaine Stine W.B., Baker L.K., Kraffts G.A., and LaDu M.J. Oligomeric and fibrillar species of amyloid-β peptides differentially affect neuronal viability. J. Biol. Chem. 277 (2002) 32046-32053
29. Esterbauer H., Schaur R.J., and Zollner H. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic. Biol. Med. 11 (1991) 81-128
30. 2+ activated hydrogen peroxide production in synaptosomes. Biochim. Biophys. Acta 1176 (1993) 208-214
31. Ravindranath V. Animal models and molecular markers for cerebral ischemia-reperfusion injury in brain. In: Packer L. (Ed). Methods in enzymology vol. 223 (1994), Academic Press, San Diego 610-619
32. Kaltschmidt B., Uherek M., Wellmann H., Volk B., and Kaltschmidt C. Inhibition of NF-kappaB potentiates amyloid beta-mediated neuronal apoptosis. Proc. Natl. Acad. Sci. USA 96 (1999) 9409-9414
33. Mattwes D.E., and Farewell V.T. Using and understanding medical statistics (1988), Karger, Basel
34. Geula C., Wu C.K., Saroff D., Lorenzo A., Yuan M., and Yankner B.A. Aging renders the brain vulnerable to amyloid beta-protein neurotoxicity. Nat. Med. 4 (1998) 827-831
35. Tamagno E., Parola M., Guglielmotto M., Santoro G., Bardini P., Marra L., Tabaton M., and Danni O. Multiple signaling events in amyloid β-induced, oxidative stress-dependent neuronal apoptosis. Free Radic. Biol. Med. 35 (2003) 45-58
36. 2 and 4-hydroxynonenal mediate amyloid β-induced neuronal apoptosis by activating JNKs and p38MAPK. Exp. Neurol. 180 (2003) 144-155
37. McLean C.A., Cherny R.A., Fraser F.W., Fuller S.J., Smith M.J., Beyreuther K., Bush A.I., and Masters C.L. Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann. Neurol. 46 (1999) 860-866
38. Lue L.F., Kuo Y.M., Roher A.E., Brachova L., Shen Y., Sue L., Beach T., Kurth J.H., Rydel R.E., and Rogers J. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am. J. Pathol. 155 (1999) 853-862
39. Walsh D.M., Klyubin I., Fadeeva J.V., Cullen W.K., Anwyl R., Wolfe M.S., Rowan M.J., and Selkoe D.J. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416 (2002) 535-539
40. Wang H.W., Pasternak J.F., Kuo H., Ristic H., Lambert M.P., Chromy B., Viola K.L., Klein W.L., Stine W.B., Krafft G.A., and Trommer B.L. Soluble oligomers of beta amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus. Brain Res. 924 (2002) 133-140
41. Mucke L., Masliah E., Yu G.Q., Mallory M., Rockenstein E.M., Tatsuno G., Hu K., Kholodenko D., Johnson-Wood K., and McConlogue L. High-level neuronal expression of Abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J. Neurosci. 20 (2000) 4050-4058
42. Morgan D., Diamond D.M., Gottschall P.E., Ugen K.E., Dickey C., Hardy J., Duff K., Jantzen P., DiCarlo G., Wilcock D., Connor K., Hatcher J., Hope C., Gordon M., and Arendash G.W. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408 (2000) 982-985
43. Dodart J.C., Bales K.R., Gannon K.S., Greene S.J., DeMattos R.B., Mathis C., DeLong C.A., Wu S., Wu X., Holtzman D.M., and Paul S.M. Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat. Neurosci. 5 (2002) 452-457
44. Kotilinek L.A., Bacskai B., Westerman M., Kawarabayashi T., Younkin L., Hyman B.T., Younkin S., and Ashe K.H. Reversible memory loss in a mouse transgenic model of Alzheimer's disease. J. Neurosci. 22 (2002) 6331-6335
45. Sponne I., Fifre A., Drouet B., Klein C., Koziel V., Pincon-Raymond M., Olivier J.L., Chambaz J., and Pillot T. Apoptotic neuronal cell death induced by the non-fibrillar amyloid-beta peptide proceeds through an early reactive oxygen species-dependent cytoskeleton perturbation. J. Biol. Chem. 278 (2003) 3437-3445
46. Mattson M.P. Pathways towards and away from Alzheimer's disease. Nature 430 (2004) 631-639
47. Butterfield D.A., and Boyd-Kimball D. Amyloid beta-peptide (1-42) contributes to the oxidative stress and neurodegeneration found in Alzheimer disease brain. Brain Pathol. 14 (2004) 426-432
48. Canevari L., Abramov A.Y., and Duchen M.R. Toxicity of amyloid beta peptide: tales of calcium, mitochondria, and oxidative stress. Neurochem. Res. 29 (2004) 637-650
49. Datki Z., Papp R., Zadori D., Soos K., Fulop L., Juhasz A., Laskay G., Hetenyi C., Mihalik E., Zarandi M., and Penke B. In vitro model of neurotoxicity of Aβ 1-42 and neuroprotection by a pentapeptide: irreversible events during the first hour. Neurobiol. Dis. 17 (2004) 507-515
50. Tyszkiewicz J.P., and Yan Z. Beta-amyloid peptides impair PKC-dependent functions of metabotropic glutamate receptors in prefrontal cortical neurons. J. Neurophysiol. 93 (2005) 3102-3111
51. Galbusera C., Facheris M., Magni F., Galimberti G., Sala G., Tremolada L., Iella V., Guerini F.R., Appollonio I., Galli-Kienle M., and Ferrarese C. Increased susceptibility to plasma lipid peroxidation in Alzheimer disease patients. Curr. Alzheimer Res. 1 (2004) 103-109
52. Boyd-Kimball D., Sultana R., Poon H.F., Lynn B.C., Casamenti F., Pepeu G., Klein J.B., and Butterfield D.A. Proteomic identification of proteins specifically oxidized by intracerebral injection of amyloid beta-peptide (1-42) into rat brain: implications for Alzheimer's disease. Neuroscience 132 (2005) 313-324
53. Yang F., Lim G.P., Begum A.N., Ubeda O.J., Simmons M.R., Ambegaoka S.S., Pingping C., Kayed R., Glabe C.G., Frautschy S.A., and Cole G.M. Curcumin inhibits formation of amyloid β oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J. Biol. Chem. 280 (2005) 5892-5901
54. Smith M.A., Casadeus G., Joseph J.A., and Perry G. Amyloid-β and -τ serve antioxidant functions in the aging and Alzheimer brain. Free Radic. Biol. Med. 33 (2002) 1194-1199
55. Lee H.G., Casadeus G., Zhu X., Takeda A., Perry G., and Smith M.A. Challenging the amyloid cascade hypothesis: senile plaques and amyloid-β as protective adaptations to Alzheimer disease. Ann. N. Y. Acad. Sci. 1019 (2004) 1-4
56. Nunomura A., Perry G., Aliev G., Hirai K., Takeda A., Balraj E.K., Jones P.K., Ghanbari H., Wataya T., Shimohama S., Chiba S., Atwood C.S., Petersen R.B., and Smith M.A. Oxidative damage is the earliest event in Alzheimer disease. J. Neuropathol. Exp. Neurol. 60 (2001) 759-767
57. Cuajungcom M.P., Goldstein L.E., Nunomura A., Smith M.A., Lim J.T., Atwood C.S., Huang X., Farrag Y.W., Perry G., and Bush A.I. Evidence that the β-amyloid plaques of Alzheimer's disease represent the redox-silencing and entombment of Aβ by zinc. J. Biol. Chem. 275 (2000) 19439-19442